You are missing a lot of private interaction we are mostly using the private feed @CRGTrades to do so, the best way to be updated is to follow us through this link, please fill in all the info needed for easy confirmation! https://www.chimeraresearchgroup.com/twitter-page/ Well, I do not think we really learned anything new yesterday in […]
March 16 Biotech Update
We are again at a decision point in the sector where it seems we are close to making another leg lower. My base case has been that there is not another major leg lower but VRX combined with the proposed Medicare part B changes have really hit the sector. We still may stave off another […]
March 14 Biotech Update
We start off the week once again without M&A and light on the news. The news we did have was positive (even if there was some discussion on twitter about it). Long story short, there is nothing today to move the sector, although perhaps having a SMID with positive data will have some pin action. […]
March 11 Biotech Update
The blast from the past continues as the market and sector continue to weaken. As cheap as large cap biotechs look it is hard to see a stock like CELG break below what was a trading range and not think it will re-test the previous lows in the lower $90s. While the market today started […]
March 9 Biotech Update
Yesterday was certainly a blast from the past with small caps getting crushed and large caps outperforming but only because they are down less than SMID. After the recent run it is not surprising that the run pauses and reverses at resistance. As one could imagine the bears will highlight this as the start of […]
SRPT – YEAR 4 DATA ANALYSIS
YEAR 4 DATA ANALYSIS Review of Eteplirsen to treat DMD By: @boscaptn, et al. Compiled From SAREPTA Public Data For Week 216 (Year 4) of Study 201/202 for Exon 51 Disclaimer: NO FINANCIAL ADVICE – The Information in this report is provided for education and informational purposes only, without any express or […]
March 7 Biotech Update
I hope everyone had a good weekend. We are off to a rather slow start with not a lot of meaningful news (again). We have a more positive sentiment background and likely the continued short covering rally, so that might be enough to move the sector higher. The trend that I want to watch this […]
March 4 Biotech Update
I am more confident in my recent speculation that we have been seeing short covering in the SMID and cash raising through the selling of large caps. ISI had a note this morning that noted something similar about the large caps where 4 of the 10 largest laggards in the S&P yesterday were biotech. He […]
Dave-Trading BIIB
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** Before we get to the meat of the trade, I want to address a recent question. How do I know how much capital to […]
March 3 Biotech Update
We are actually seeing something interesting in the sector where small caps are outperforming large caps (by a wide margin). Are investors finally starting to get more comfortable and increasing their risk? Could certainly be the case but it also is consistent with the short covering rally thesis. Just about all of the SMID biotech […]
March 2 Biotech Update
The market has a good rally off of the lows yesterday and despite still feeling concerned about the market it has actually had a nice rally in the second half of February. The problem is that two weeks of good price action is not nearly enough to get rid of the damage especially in the […]
February 29 Biotech Update
I would have expected more action to start the week but it has been pretty quiet. It looks like we are left to the sentiment tides once again as there is nothing I see on the news front that can make a dent in either direction. As such, I will spend today mainly talking about […]
Biotech Inflection Point – Watch List-2
Following my last technical analysis “Biotech Inflection Point – Watch List-1” I will keep adding names to our watch list with some beaten down tickers, we can find many deep value biotech stocks in the recent pullback, some are trading at or very close to their cash level, at this point their assets are […]
February 26 Biotech Update
I was supposed to be back from travelling yesterday but the weather cancelled my flight but I am back at it today. Of course, I did not miss a lot of bullish action although there has been some SMID earnings that I want to touch on. We seem to be back in the pattern that […]
Buy DeLo, Sell DeHigh – RUT
*** Jason DeLorenzo is an income options trader. He trades on indexes mostly, but will trade positions based on CRG theses*** On 2/18 close to the market close, Joe tweeted this: “Joe @GantosJ Feb 18: The “Three Gaps Up” pattern $SPY $IBB $XBI is only a warning that exhaustion in the way, BUT expanding […]
February 22 Biotech Update
It is a good start to the week as the markets open green and everything seems to be heading higher. One could argue that the trend of selling the rallies has broken but I still think we need to decisively put in a higher low and higher high before we can get any confidence in […]
February 19 Biotech Update
We are getting the pullback after that quick rip your face off rally and so now is the real moment of truth. Did the rally simply reset the relative strength to allow another leg lower or will buyers step in and buy this pullback? As I noted before there is no way of knowing and […]
Dave-Trading – GILD
Gilead – GILD *** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** Dave LOVES writing about GILD. Their combined Hep C franchise is by all metrics the most successful launch ever, so it is […]
February 18 Biotech Update
We continue to have a short covering rally as the most shorted stocks continue to outperform. This seems to be the mantra of people who want to discount the move but as I said before there is no reason to suspect that the bounce off the lows would be anything but a short covering rally. […]
February 17 Biotech Update
We are having a green opening after back to back green days, which is pretty rare this year. We have obviously been due for a bounce and whether this is the bottom or a dead cat bounce is yet to be determined. This move is driven by short covering (the most shorted stocks are greatly […]
